Home・Lista de Ações・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Abrir

SetorSaúde

82.32 -0.82

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

81.96

Máximo

83.56

Indicadores-chave
By Trading Economics
Rendimento	11M -156M
Vendas	28M 222M
EPS	-0.78
Margem de lucro	-70.082
Funcionários	999
EBITDA	-24M -137M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+30.89% upside

Dividendos
By Acuity
Próximos Ganhos	28 de out. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-981M 16B
Abertura anterior	83.14
Fecho anterior	82.32

Sentimento de Notícias

By Acuity

50%

171 / 340 Ranking em Healthcare

Bridgebio Pharma Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

20 de ago. de 2026, 19:46 UTC

Correlated Moves

Shares lower amid broader biotechnology sector decline.

19 de ago. de 2026, 23:01 UTC

BridgeBio Pharma Inc shares are higher in after-market trading, recovering from earlier lows. Broader market gains in cryptocurrencies may reflect a shift in investor sentiment.

18 de ago. de 2026, 20:06 UTC

Social Media

BridgeBio Pharma Inc shares are higher, supported by social media discussions on Attruby's potential market share and anticipation for upcoming clinical data.

14 de ago. de 2026, 20:06 UTC

Social Media

News

BridgeBio Pharma's shares decline as it announces a secondary offering of 5 million shares priced at $78.00, managed by KKR and others.

13 de ago. de 2026, 23:01 UTC

News

BridgeBio Pharma Inc shares are lower in after-market hours following the announcement of a secondary public offering of 5,000,000 shares on behalf of KKR.

12 de ago. de 2026, 19:51 UTC

News

Social Media

BridgeBio Pharma Inc shares are lower today despite multiple analyst price target upgrades. Management noted waning physician enthusiasm for a combination therapy.

11 de ago. de 2026, 22:36 UTC

BridgeBio Pharma Inc. shares are lower in after-market trading, fluctuating within a narrow range with no specific news identified.

10 de ago. de 2026, 23:21 UTC

News

Social Media

BridgeBio Pharma Inc. reported second-quarter revenues of $243.7 million, exceeding expectations. Shares are higher in after-market trading amid positive reception for Attruby.

7 de ago. de 2026, 20:03 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc is gaining traction amid strong biotech sector performance. Cantor Fitzgerald lists it as a top pick ahead of its earnings report.

6 de ago. de 2026, 19:16 UTC

Social Media

BridgeBio Pharma Inc's shares are higher, reflecting a modest gain since Wednesday's close amid mixed market sentiment ahead of the non-farm payrolls report.

5 de ago. de 2026, 19:16 UTC

BridgeBio Pharma Inc. shares are lower today, with no specific news identified. The stock retraced from earlier gains, reflecting broader market trends.

4 de ago. de 2026, 19:36 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc shares rise as Piper Sandler sets a price target of $111 following the LGMD Scientific Summit. Biotech sector momentum supports the increase.

3 de ago. de 2026, 20:06 UTC

BridgeBio Pharma Inc shares are lower today, breaking from a recent trend of higher daily closes. No specific news was identified to explain the decline.

31 de jul. de 2026, 19:56 UTC

Correlated Moves

Social Media

BBIO shares decline, continuing a three-day trend amid sector weakness.

30 de jul. de 2026, 20:21 UTC

Correlated Moves

BridgeBio Pharma Inc shares rose in after-market trading, reflecting positive market sentiment. The stock's performance aligns with an upward trend in the Russell 2000 Index.

29 de jul. de 2026, 17:36 UTC

BridgeBio Pharma Inc shares are lower today, reaching a pre-market low before a slight recovery. No specific news was identified to explain the decline.

28 de jul. de 2026, 19:07 UTC

Correlated Moves

BBIO shares lower today amid declining biotech sector sentiment.

27 de jul. de 2026, 18:26 UTC

Social Media

BridgeBio Pharma shares are higher, supported by Bank of America’s positive pipeline commentary and a $35 million revenue estimate increase for 2026.

Comparação entre Pares

Variação de preço

Bridgebio Pharma Inc Previsão

Preço-alvo

By TipRanks

30.89% parte superior

Previsão para 12 meses

Média 108.56 USD 30.89%

Máximo 157 USD

Mínimo 94 USD

Com base em 17 analistas de Wall Street que oferecem metas de preço de 12 meses para Bridgebio Pharma Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

17 ratings

Comprar

Manter

Vender

Com base em 17 analistas que deram avaliações de ações para Bridgebio Pharma Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

171 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.